Dr Robertson and colleagues must be congratulated for holding up the "red flag of classification" to the "bulls of gynaecological cytology".' Their timing is excellent, particularly as the frailty of the current reporting system becomes increasingly evident.
A basic premise in the currently recommended terminology and management of cervical smears is that the degree of dyskaryosis correlates with the grade of cervical intraepithelial neoplasia (CIN) In advocating a low and high grade method of reporting, the Bethesda system is cited by us only as an example. We accept that it is rather too elaborate. However, unlike Dr Slater, we hesitate to include "borderline changes", with wart virus and mild dyskaryosis as a low grade abnormality. Among cytopathologists "borderline" seems almost to have achieved the status of a diagnostic entity. Our experience is that in practice it merely reflects uncertainty in interpretation of a smear. Reparative changes in the cervix, papillomavirus infection, or atypical cells due to inflammation can all present difficulties. The latter may occasionally be confused with invasive cancer, and a six month repeat smear would be inappropriate. We feel that such reports should describe the diagnostic difficulty, advise on further action, and be summarised as "no diagnosis".
To the lay person the term "borderline" is unsatisfactory. It could be quite frightening for some women, giving the impression of a limbo bordering on (?) the abyss. It is not a diagnostic entity and, like the unicorn which had similar problems of identity, should be allowed to pass into mythology. I). This seems to be independent of the value of VIII:C in the third trimester, and presumably is explained by a failure of the primary haemostatic defect to improve in pregnancy. Importantly, secondary PPH occurred to a similar extent in both groups (2/12 type I and 3/11 type II-22% overall) and may be more dangerous as it often occurs after discharge from hospital.
The guidelines should serve to raise awareness and maintain vigilance in the management of von Willbrand's disease in pregnancy. We would add that with reference to secondary PPH, while the administration of prophylactic von Willebrand factor (vWF) containing .. .........................................   ...............   -,,e,,. ... ... orres )onc ence ...
